MAP2 and neoplasm: MAP2 knockdown modestly altered CD8+ T-cell–mediated killing under D + O + C or D + C treatment compared to control conditions (Fig. 7d–e), suggesting a potential role of MAP2 in shaping tumor susceptibility to immune cytotoxicity.